[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1883393A2 - Stabilized oral pharmaceutical compositions of cephalosporins - Google Patents

Stabilized oral pharmaceutical compositions of cephalosporins

Info

Publication number
EP1883393A2
EP1883393A2 EP06809918A EP06809918A EP1883393A2 EP 1883393 A2 EP1883393 A2 EP 1883393A2 EP 06809918 A EP06809918 A EP 06809918A EP 06809918 A EP06809918 A EP 06809918A EP 1883393 A2 EP1883393 A2 EP 1883393A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
cephalosporin
maize starch
oral
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06809918A
Other languages
German (de)
French (fr)
Inventor
Himadri Sen
Makarand Avachat
Sanjay Wagh
Bharat Metkar
Abhijit Dhamne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of EP1883393A2 publication Critical patent/EP1883393A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Definitions

  • the invention relates to oral pharmaceutical compositions of cephalosporins, particularly Cefpodoxime and a method for enhancing the stability of these oral pharmaceutical compositions.
  • Cephalosporins are one of the mainstays of antibacterial therapy today.Cefpodoxime proxetil, (R, S)-i-(isopropoxycarbonyloxy) ethyl - (+)-(6R, 7R)-7-[2-(2-amino-4-thiazolyl)-2-((Z)-methoxyimino)acetamido]-3- methoxymethyl-8-oxo-5-thia-1 -azabicyclo [4,2,0]oct-2-en-2- carboxylate, disclosed in U.S. Pat. No.
  • 4,486,425 is a cephalosporin ester pro-drug which, when orally administered, is absorbed and de-esterified through rapid hydrolysis by esterases present on the intestinal mucosa to release its active metabolite, the third generation cephalosporin, cefpodoxime, an antibacterial agent.
  • Cefpodoxime Proxetil is a valuable antibiotic characterized by high broad- spectrum activity against gram-positive and gram-negative microorganisms. Cefpodoxime exhibits a high degree of ⁇ - lactamase stability and is stable towards hydrolysis by the most commonly found plasmid-mediated ⁇ - lactamases. It shares the familiar and relatively benign tolerability profile of other broad spectrum cephalosporins with regard to both the incidence and severity of adverse events thus, rendering it as an effective alternative to currently used ⁇ - lactams for empirical therapy in a wide range of community acquired infections in both adult and pediatric patients.
  • Cefpodoxime proxetil is a .highly hydrophobic drug that has a tendency to form a gel in aqueous media, which thereby results in slow dissolution and hence poor bioavailability. It is therefore necessary that the pharmaceutical composition be formulated such that bridging of molecules to form a gel is prevented and thereby, the dissolution is improved. Apart from ensuring bioavailability, a pharmaceutical dosage form also needs to be stable. The stabilization of cephalosporins such as cefpodoxime, which are highly prone to degradation in the presence of moisture and temperature, is a challenging task for the formulator. The applicants have now surprisingly found that the use of maize starch with moisture content of not more than 2% in oral, pharmaceutical compositions comprising Cefpodoxime proxetil significantly improves stability. •
  • Another object of the invention is to provide a process for preparing an oral, stable, pharmaceutical composition of a cephalosporin comprising the steps of reducing the size of the cephalosporin particles and mixing with maize starch and one or more excipients.
  • Another object of the invention is to provide a process for preparing an oral, stable, pharmaceutical composition of Cefpodoxime proxetil comprising the steps of reducing the size of the cefpodoxime proxetil particles and mixing with maize starch and one or more excipients.
  • cephalosporins include, but are not limited to Cefixime, cefpodoxime proxetil, cefuroxime axetil, Cefdinir, cefaclor, cephalexin and the like.
  • cefpodoxime covers cefpodoxime base and the esters of cefpodoxime such as cefpodoxime proxetil and these terms are interchangeable.
  • the maize (corn) starch used has moisture content of not more than 2% (low moisture containing maize or corn starch).
  • the low moisture containing starch is maize (corn) starch (e.g. marketed under the brand name of Unipure FL) that has been carefully dried under controlled conditions to meet moisture specifications that is lower than that found in conventional starches.
  • the maize starch with moisture content of not more than 2% can be used in a stability- enhancing amount.
  • stability enhancing amount is meant an amount which stabilizes a cephalosporin, particularly cefpodoxime proxetil in a composition as compared to a composition which does not contain maize starch and this amount can range from 1-99%.
  • the maize starch with moisture content of not more than 2% can be used in a range from 5 to 50%.
  • dosage form' includes within its scope but is not limited to tablets, capsules, suspensions, suppositories, semisolid preparations and the like.
  • dosage forms can additionally comprise one or more excipients, which are well known to the person skilled in the art.
  • Processes well known to the person skilled in the art can be used to prepare these dosage forms e.g. a process for preparing an oral, stable, pharmaceutical composition of a cephalosporin can comprise the steps of reducing the size of the cephalosporin particles and mixing with maize starch and one or more excipients.
  • a process for preparing an oral, stable, pharmaceutical composition of Cefpodoxime proxetil can comprise the steps of reducing the size of the cefpodoxime proxetil particles and mixing with maize starch and one or more excipients.
  • a preferred embodiment involves the use of maize starch with moisture content of not more than 2% in an oral, pharmaceutical suspension composition of cephalosporins particularly, Cefpodoxime proxetil.
  • composition includes within its scope but is not limited to compositions selected from the group consisting of pellets for suspension which can be coated or uncoated, granules for suspension, in the form of a unit dose packet (sometimes referred to in the art as a "sachet"), in the form of a suspension made from a unit dose packet, in the form of a powder for oral suspension, in the form of a dose sipping device and in the form of an oral suspension per se and combinations of these e.g. coated pellets filled in a dose sipping device or in a sachet.
  • a unit dose packet sometimes referred to in the art as a "sachet”
  • suspension when a unit dose packet is constituted, it is probably mainly in the form of a suspension if reconstituted according to directions, although the extent of suspension versus solution depends on a number of factors such as pH.
  • the use of the term "suspension” herein is intended to embrace liquids containing cefpodoxime axetil partially in suspension and partially in solution.
  • a further preferred embodiment involves the use of maize starch with a moisture content of not more than 2% in a powder for suspension composition of cephalosporins, particularly cefpodoxime proxetil.
  • the oral, pharmaceutical suspension composition can additionally comprise of atleast one excipient depending upon the dosage form e.g. whether as pellets or as granules for suspension and so on.
  • the excipient can be one or more selected from the group consisting of diluents, binders, disintegrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
  • One excipient can perform more than one function.
  • Diluents which include, but are not limited to mannitol, sucrose, starch, lactose, dicalcium phosphate, xylitol, sorbitol, micro-crystalline cellulose and the like can be used.
  • Binders which include, but are not limited to, alkylcelluloses such as methyl cellulose, hydroxyalkylcelluloses such as hydroxypropylcellulose, low substituted hydroxypropylcellulose and hydroxypropyl methylcellulose, sodium carboxymethylcellulose or mixtures thereof, pregelatinised maize starch or polyvinylpyrrolidone can be used.
  • Disintegrants which include but are not limited to, crospovidone, sodium starch glycolate, starches such as maize starch and dried starch, croscarmellose sodium and cellulose products such as microcrystalline cellulose, microfine cellulose, low substituted hydroxypropylcellulose and the like.
  • Suitable wetting agents can include, but are not limited to, surfactants, either singly or in admixture. Examples of surfactants include, but are not limited to, the polysorbates, sodium lauryl sulphate, poloxamers and the like.
  • Suitable sweeteners include, but are not limited to, natural sweeteners such as sugars e.g. fructose, glucose, sucrose, sugar alcohols such as mannitol, sorbitol or mixtures thereof and artificial sweeteners such as sodium saccharine, sodium cyclamate and aspartame.
  • natural sweeteners such as sugars e.g. fructose, glucose, sucrose, sugar alcohols such as mannitol, sorbitol or mixtures thereof
  • artificial sweeteners such as sodium saccharine, sodium cyclamate and aspartame.
  • Suitable thickening agents function as suspending agents and include, but are not limited to, hydrocolloid gums known for such purpose, examples of which include xanthan gum, guar gum, locust bean gum, gum tragacanth, microcrystalline cellulose and carboxymethylcellulose sodium, sodium carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose and the like or mixtures thereof.
  • Dispersing agents include, but are not limited to, colloidal silicon dioxide and surfactants, wherein the surfactant is used alone or as an admixture with one or more surfactant. Combinations of colloidal silicon dioxide with one or more surfactants can also be used.
  • the oral, pharmaceutical suspension composition may also contain a pH - stabilizing agent to maintain a desired pH upon reconstitution, as discussed above.
  • a pH - stabilizing agent encompasses buffers and pH - altering agents. Suitable pH - stabilizing agents include tribasic sodium phosphate, anhydrous sodium carbonate, glycine, citric acid and the like or mixtures thereof.
  • Flavouring agents are well known to persons skilled in the art and include, but are not limited to fruity flavours. Banana Flavour or combinations thereof with other flavours are preferred.
  • Taste enhancing agents include, but are not limited to, sodium chloride, glycine, citric acid, tartaric acid and the like and mixtures thereof.
  • Suitable preservatives include, but are not limited to, benzoic acid and sorbic acid and their salts, methyl paraben, butylparaben, propylparaben and the like.
  • Suitable coloring agents include, but are not limited to, titanium dioxide pigments, lake colours and iron oxide pigments.
  • Lubricants and flow aids such as, but not limited to, talc, magnesium stearate, calcium silicate and colloidal silicon dioxide can also be used.
  • oral suspension compositions can be prepared by means well known to those skilled in the art.
  • the powder for suspension formulations can be prepared by a process comprising the steps of reducing the size of the cephalosporin and mixing with one or more excipients selected from the group consisting of diluents, binders, d is integrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
  • excipients selected from the group consisting of diluents, binders, d is integrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
  • the powder for suspension formulations can be prepared by a process comprising the steps of reducing the size of Cefpodoxime proxetil and mixing with one or more excipients selected from the group consisting of diluents, binders, disintegrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
  • excipients selected from the group consisting of diluents, binders, disintegrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
  • the suspension can be reconstituted using potable water or using juices such as apple juice, strawberry juice, orange juice or using aerated or carbonated preparations.
  • juices such as apple juice, strawberry juice, orange juice or using aerated or carbonated preparations.
  • vehicles well known to persons skilled in the art such as propylene glycol, glycerin, sorbitol, liquid glucose and the like can also be used, at levels well known to the persons skilled in the art, in addition to water.
  • the invention provides for an oral, pharmaceutical composition, which is stable and has adequate bioavailability, the composition comprising a cephalosporin particularly cefpodoxime proxetil and maize starch.
  • a cephalosporin particularly cefpodoxime proxetil and maize starch By 'adequate bioavailability' is meant a composition which is bioequivalent to the commercially available oral, pharmaceutical compositions of cephalosporins particularly cefpodoxime proxetil.
  • Cefpodoxime proxetil was micronized and sifted using an appropriate screen on a vibratory sifter.
  • Table 1 Comparison of the stability profile of powder for oral suspension of Cefpodoxime proxetil formulation I (with maize starch) and formulation Il (without maize starch) immediately after reconstitution and 10 days after reconstitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oral pharmaceutical compositions of cephalosporins, particularly Cefpodoxime, aproces for preparing the same and a method for enhancing the stability of these oral pharmaceutical compositions. The oral pharmaceutical composition of a cephalosporin, is stable and has adequate bio-availability, and comprises the cephalosporin and maize starch. The process for preparing an oral pharmaceutical composition of a cephalosporin comprises the steps of reducing the size of the cephalosporin and mixing with maize starch and one or more excipients. The method of enhancing the stability profile of a cephalosporin in a pharmaceutical composition comprises contacting the cephalosporin with a stability - enhancing amount of maize starch with a moisture content of not more than 2%. The oral suspension exhibits an improved stability profile as compared to an oral suspension pharmaceutical composition comprising the said cephalosporin which does not contain maize starch in a stability - enhancing amount.

Description

STABILIZED ORAL PHARMACEUTICAL COMPOSITIONS OF CEPHALOSPORINS
FIELD OF INVENTION
The invention relates to oral pharmaceutical compositions of cephalosporins, particularly Cefpodoxime and a method for enhancing the stability of these oral pharmaceutical compositions.
BACKGROUND OF THE INVENTION
Cephalosporins are one of the mainstays of antibacterial therapy today.Cefpodoxime proxetil, (R, S)-i-(isopropoxycarbonyloxy) ethyl - (+)-(6R, 7R)-7-[2-(2-amino-4-thiazolyl)-2-((Z)-methoxyimino)acetamido]-3- methoxymethyl-8-oxo-5-thia-1 -azabicyclo [4,2,0]oct-2-en-2- carboxylate, disclosed in U.S. Pat. No. 4,486,425, is a cephalosporin ester pro-drug which, when orally administered, is absorbed and de-esterified through rapid hydrolysis by esterases present on the intestinal mucosa to release its active metabolite, the third generation cephalosporin, cefpodoxime, an antibacterial agent.
Cefpodoxime Proxetil is a valuable antibiotic characterized by high broad- spectrum activity against gram-positive and gram-negative microorganisms. Cefpodoxime exhibits a high degree of β - lactamase stability and is stable towards hydrolysis by the most commonly found plasmid-mediated β - lactamases. It shares the familiar and relatively benign tolerability profile of other broad spectrum cephalosporins with regard to both the incidence and severity of adverse events thus, rendering it as an effective alternative to currently used β - lactams for empirical therapy in a wide range of community acquired infections in both adult and pediatric patients.
Like many cephalosporins, Cefpodoxime proxetil is a .highly hydrophobic drug that has a tendency to form a gel in aqueous media, which thereby results in slow dissolution and hence poor bioavailability. It is therefore necessary that the pharmaceutical composition be formulated such that bridging of molecules to form a gel is prevented and thereby, the dissolution is improved. Apart from ensuring bioavailability, a pharmaceutical dosage form also needs to be stable. The stabilization of cephalosporins such as cefpodoxime, which are highly prone to degradation in the presence of moisture and temperature, is a challenging task for the formulator. The applicants have now surprisingly found that the use of maize starch with moisture content of not more than 2% in oral, pharmaceutical compositions comprising Cefpodoxime proxetil significantly improves stability. •
OBJECTS OF THE INVENTION It is the principal object of the present invention to formulate oral pharmaceutical compositions of Cefpodoxime proxetil in which gel formation is minimized and dissolution is improved.
It is a further object of the present invention to formulate oral pharmaceutical compositions comprising Cefpodoxime as a powder for oral suspension to provide a convenient method of preventing gel formation and ensuring adequate bioavailability.
It is another object of the present invention to provide oral, pharmaceutical compositions comprising a cephalosporin, which have adequate bioavailability and stability, the composition comprising cephalosporin and maize starch.
It is another object of the present invention to provide oral, pharmaceutical compositions comprising Cefpodoxime proxetil, which have adequate bioavailability and stability, the composition comprising Cefpodoxime and maize starch.
It is another object of the present invention to provide a method of enhancing the stability profile of cephalosporins in a pharmaceutical composition, the method comprising of contacting the cephalosporin with a stability - enhancing amount of maize starch with moisture content of not more than 2%. It is another object of the present invention to provide a method of enhancing the stability profile of Cefpodoxime proxetil in a pharmaceutical composition, the method comprising of contacting Cefpodoxime proxetil with a stability - enhancing amount of maize starch with moisture content of not more than 2%.
Another object of the invention is to provide a process for preparing an oral, stable, pharmaceutical composition of a cephalosporin comprising the steps of reducing the size of the cephalosporin particles and mixing with maize starch and one or more excipients.
Another object of the invention is to provide a process for preparing an oral, stable, pharmaceutical composition of Cefpodoxime proxetil comprising the steps of reducing the size of the cefpodoxime proxetil particles and mixing with maize starch and one or more excipients.
DETAILED DESCRIPTION OF INVENTION
The invention pertains to oral, pharmaceutical compositions of cephalosporins. Examples of cephalosporins include, but are not limited to Cefixime, cefpodoxime proxetil, cefuroxime axetil, Cefdinir, cefaclor, cephalexin and the like.
As used herein, the term cefpodoxime covers cefpodoxime base and the esters of cefpodoxime such as cefpodoxime proxetil and these terms are interchangeable.
The maize (corn) starch used has moisture content of not more than 2% (low moisture containing maize or corn starch). The low moisture containing starch is maize (corn) starch (e.g. marketed under the brand name of Unipure FL) that has been carefully dried under controlled conditions to meet moisture specifications that is lower than that found in conventional starches. The maize starch with moisture content of not more than 2% can be used in a stability- enhancing amount. By "stability - enhancing amount " is meant an amount which stabilizes a cephalosporin, particularly cefpodoxime proxetil in a composition as compared to a composition which does not contain maize starch and this amount can range from 1-99%. In a preferred embodiment, the maize starch with moisture content of not more than 2% can be used in a range from 5 to 50%.
The term ' dosage form' includes within its scope but is not limited to tablets, capsules, suspensions, suppositories, semisolid preparations and the like. Such dosage forms can additionally comprise one or more excipients, which are well known to the person skilled in the art. Processes well known to the person skilled in the art can be used to prepare these dosage forms e.g. a process for preparing an oral, stable, pharmaceutical composition of a cephalosporin can comprise the steps of reducing the size of the cephalosporin particles and mixing with maize starch and one or more excipients. In a preferred embodiment, a process for preparing an oral, stable, pharmaceutical composition of Cefpodoxime proxetil can comprise the steps of reducing the size of the cefpodoxime proxetil particles and mixing with maize starch and one or more excipients.
A preferred embodiment involves the use of maize starch with moisture content of not more than 2% in an oral, pharmaceutical suspension composition of cephalosporins particularly, Cefpodoxime proxetil.
The term "suspension composition" includes within its scope but is not limited to compositions selected from the group consisting of pellets for suspension which can be coated or uncoated, granules for suspension, in the form of a unit dose packet (sometimes referred to in the art as a "sachet"), in the form of a suspension made from a unit dose packet, in the form of a powder for oral suspension, in the form of a dose sipping device and in the form of an oral suspension per se and combinations of these e.g. coated pellets filled in a dose sipping device or in a sachet. It is noted that when a unit dose packet is constituted, it is probably mainly in the form of a suspension if reconstituted according to directions, although the extent of suspension versus solution depends on a number of factors such as pH. The use of the term "suspension" herein is intended to embrace liquids containing cefpodoxime axetil partially in suspension and partially in solution.
A further preferred embodiment involves the use of maize starch with a moisture content of not more than 2% in a powder for suspension composition of cephalosporins, particularly cefpodoxime proxetil.
The oral, pharmaceutical suspension composition can additionally comprise of atleast one excipient depending upon the dosage form e.g. whether as pellets or as granules for suspension and so on. The excipient can be one or more selected from the group consisting of diluents, binders, disintegrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like. One excipient can perform more than one function.
Diluents, which include, but are not limited to mannitol, sucrose, starch, lactose, dicalcium phosphate, xylitol, sorbitol, micro-crystalline cellulose and the like can be used.
Binders which include, but are not limited to, alkylcelluloses such as methyl cellulose, hydroxyalkylcelluloses such as hydroxypropylcellulose, low substituted hydroxypropylcellulose and hydroxypropyl methylcellulose, sodium carboxymethylcellulose or mixtures thereof, pregelatinised maize starch or polyvinylpyrrolidone can be used.
Disintegrants, which include but are not limited to, crospovidone, sodium starch glycolate, starches such as maize starch and dried starch, croscarmellose sodium and cellulose products such as microcrystalline cellulose, microfine cellulose, low substituted hydroxypropylcellulose and the like. Suitable wetting agents can include, but are not limited to, surfactants, either singly or in admixture. Examples of surfactants include, but are not limited to, the polysorbates, sodium lauryl sulphate, poloxamers and the like.
Suitable sweeteners include, but are not limited to, natural sweeteners such as sugars e.g. fructose, glucose, sucrose, sugar alcohols such as mannitol, sorbitol or mixtures thereof and artificial sweeteners such as sodium saccharine, sodium cyclamate and aspartame.
Suitable thickening agents function as suspending agents and include, but are not limited to, hydrocolloid gums known for such purpose, examples of which include xanthan gum, guar gum, locust bean gum, gum tragacanth, microcrystalline cellulose and carboxymethylcellulose sodium, sodium carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose and the like or mixtures thereof.
Dispersing agents include, but are not limited to, colloidal silicon dioxide and surfactants, wherein the surfactant is used alone or as an admixture with one or more surfactant. Combinations of colloidal silicon dioxide with one or more surfactants can also be used.
The oral, pharmaceutical suspension composition may also contain a pH - stabilizing agent to maintain a desired pH upon reconstitution, as discussed above. The term "pH - stabilizing agent" encompasses buffers and pH - altering agents. Suitable pH - stabilizing agents include tribasic sodium phosphate, anhydrous sodium carbonate, glycine, citric acid and the like or mixtures thereof.
Flavouring agents are well known to persons skilled in the art and include, but are not limited to fruity flavours. Banana Flavour or combinations thereof with other flavours are preferred. Taste enhancing agents include, but are not limited to, sodium chloride, glycine, citric acid, tartaric acid and the like and mixtures thereof.
Suitable preservatives include, but are not limited to, benzoic acid and sorbic acid and their salts, methyl paraben, butylparaben, propylparaben and the like.
Suitable coloring agents include, but are not limited to, titanium dioxide pigments, lake colours and iron oxide pigments.
Lubricants and flow aids such as, but not limited to, talc, magnesium stearate, calcium silicate and colloidal silicon dioxide can also be used.
All these excipients can be used at levels well known to the persons skilled in the art.
The oral suspension compositions can be prepared by means well known to those skilled in the art.
For example, the powder for suspension formulations can be prepared by a process comprising the steps of reducing the size of the cephalosporin and mixing with one or more excipients selected from the group consisting of diluents, binders, d is integrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
In a preferred embodiment, the powder for suspension formulations can be prepared by a process comprising the steps of reducing the size of Cefpodoxime proxetil and mixing with one or more excipients selected from the group consisting of diluents, binders, disintegrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
Where applicable, the suspension can be reconstituted using potable water or using juices such as apple juice, strawberry juice, orange juice or using aerated or carbonated preparations. Alternatively, for the suspension per se, vehicles well known to persons skilled in the art, such as propylene glycol, glycerin, sorbitol, liquid glucose and the like can also be used, at levels well known to the persons skilled in the art, in addition to water.
Thus, the invention provides for an oral, pharmaceutical composition, which is stable and has adequate bioavailability, the composition comprising a cephalosporin particularly cefpodoxime proxetil and maize starch. By 'adequate bioavailability' is meant a composition which is bioequivalent to the commercially available oral, pharmaceutical compositions of cephalosporins particularly cefpodoxime proxetil.
The application of the invention can be seen by the following, non limiting examples:
EXAMPLE 1.
Brief manufacturing procedure:
1. Cefpodoxime proxetil was micronized and sifted using an appropriate screen on a vibratory sifter.
2. All the other ingredients were sifted through an appropriate screen using a vibratory sifter.
3. One third of the sucrose was milled.
4. All the ingredients were mixed using an octagonal blender.
5. The blend was filled in HDPE bottles. Table 1 : Comparison of the stability profile of powder for oral suspension of Cefpodoxime proxetil formulation I (with maize starch) and formulation Il (without maize starch) immediately after reconstitution and 10 days after reconstitution
*0th day = Analysis done immediately after reconstitution
*10th day= Analysis done after storage of the reconstituted suspension for 10 days at the specified condition.
As can be seen, there is a significant difference in the assay values with the formulation containing stability - enhancing amount of maize starch showing adequate stability as opposed to the formulation, which does not contain it.

Claims

1. An oral pharmaceutical composition of a cephalosporin, which is stable and has adequate bioavailability, the composition comprising the cephalosporin and maize starch.
2. An oral pharmaceutical composition of Cefpodoxime, which is stable and has adequate bioavailability, the composition comprising Cefpodoxime proxetil and maize starch.
3. An oral pharmaceutical composition of a cephalosporin according to claim 1 , wherein the maize starch has a moisture content of not more than 2%.
4. An oral pharmaceutical composition of a cephalosporin according to claim 1 , wherein a stability - enhancing amount of maize starch is present.
5. An oral pharmaceutical composition of a cephalosporin according to claim 1 , which is in the form of tablets, capsules, suspensions, suppositories, semisolid preparations and the like.
6. An oral pharmaceutical composition of a cephalosporin according to claim 1 , wherein the pharmaceutical composition is an oral suspension being a composition selected from the group comprising of pellets for suspension which can be coated or uncoated, granules for suspension, in the form of a unit dose packet (sachet), in the form of a suspension made from a unit dose packet, in the form of a powder for oral suspension, in the form of a dose sipping device and in the form of an oral suspension.
7. An oral pharmaceutical composition of a cephalosporin according to claim 1 , wherein maize starch is present in an amount between 1 - 20%.
8. An oral pharmaceutical composition of a cephalosporin according to claim 1 , wherein the composition comprises of atleast one additional excipient selected from the group consisting of diluents, binders, disintegrants, stabilizers, wetting agents, sweeteners, thickening agents, dispersing agents, pH - stabilizing agents, flavoring agents, taste - enhancing agents, preservatives, coloring agents, lubricants and flow - aids and the like.
9. A process for preparing an oral pharmaceutical composition of a cephalosporin comprising the steps of reducing the size of the cephalosporin and mixing with maize starch and one or more excipients.
10. A process for preparing an oral pharmaceutical composition of Cefpodoxime comprising the steps of reducing the size of Cefpodoxime proxetil and mixing with maize starch and one or more excipients.
11. A method of enhancing the stability profile of a cephalosporin in a pharmaceutical composition, the method comprising of contacting the cephalosporin with a stability - enhancing amount of maize starch with a moisture content of not more than 2%
12. A method of enhancing the stability profile of Cefpodoxime proxetil in a pharmaceutical composition, the method comprising of contacting Cefpodoxime proxetil with stability - enhancing amount of maize starch with a moisture content of not more than 2%.
13.An oral suspension pharmaceutical composition comprising of a cephalosporin and maize starch in a stability - enhancing amount which exhibits an improved stability profile as compared to an oral suspension pharmaceutical composition comprising the said cephalosporin which does not contain maize starch in a stability - enhancing amount.
14.An oral suspension pharmaceutical composition comprising of Cefpodoxime proxetil and maize starch in a stability - enhancing amount which exhibits an improved stability profile as compared to an oral suspension pharmaceutical composition comprising cefpodoxime proxetil which does not contain maize starch in a stability - enhancing amount.
EP06809918A 2005-05-05 2006-05-05 Stabilized oral pharmaceutical compositions of cephalosporins Withdrawn EP1883393A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN556MU2005 2005-05-05
PCT/IN2006/000160 WO2007017895A2 (en) 2005-05-05 2006-05-05 Stabilized oral pharmaceutical compositions of cephalosporins

Publications (1)

Publication Number Publication Date
EP1883393A2 true EP1883393A2 (en) 2008-02-06

Family

ID=37672426

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06809918A Withdrawn EP1883393A2 (en) 2005-05-05 2006-05-05 Stabilized oral pharmaceutical compositions of cephalosporins

Country Status (3)

Country Link
EP (1) EP1883393A2 (en)
JP (1) JP2008540403A (en)
WO (1) WO2007017895A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201007107A1 (en) * 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Formulations of cefpodoxime proxetil containing taste regulating agent.
TR201007106A1 (en) * 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Cefpodoxime proxetil formulations.
TR201009167A2 (en) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical granules containing cephalosporin.
TR201009168A2 (en) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Water dispersible cefpodoxime proxetil formulations.
JP2013147488A (en) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd Solid preparation
CN105377236B (en) * 2013-07-18 2019-04-23 桑多斯股份公司 Mixture of powders for antibiotic dry syrup preparation
CN103479589B (en) * 2013-09-22 2016-04-13 海南葫芦娃制药有限公司 cefpodoxime proxetil dispersible tablet and preparation method thereof
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1132583A (en) * 1964-12-16 1968-11-06 Glaxo Lab Ltd Pharmaceutical compositions containing cephalosporins
DE2259646C2 (en) * 1972-12-06 1984-11-22 Hoechst Ag, 6230 Frankfurt High-dose tablets of cephalosporin derivatives, as well as processes for their manufacture
GB1464551A (en) * 1973-02-08 1977-02-16 Gist Brocades Nv Alpha-substituted amino-phenylacetamido penicillanic acid and cephalosporanic acid derivatives methods for their preparation and their use
ATE303149T1 (en) * 2001-02-27 2005-09-15 Ranbaxy Lab Ltd ORAL PHARMACEUTICAL COMPOSITION OF CEFPODOXIM PROXETIL
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007017895A2 *

Also Published As

Publication number Publication date
WO2007017895A3 (en) 2007-04-19
JP2008540403A (en) 2008-11-20
WO2007017895A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
WO2007017895A2 (en) Stabilized oral pharmaceutical compositions of cephalosporins
EP1446126A1 (en) Coated particulate cefuroxime axetil compositions
EP1181018B1 (en) Ziprasidone suspension
EP2366379B1 (en) Cefdinir formulation with improved dissolution rate
EP1389462B1 (en) Amorphous cefditoren pivoxil composition and process for producing the same
WO2008057058A1 (en) Oral pharmaceutical compositions
WO2009123304A1 (en) Fine granules having improved suspension performance in water
US20130129791A1 (en) Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2012060786A2 (en) Cefpodoxime proxetil formulations comprising viscosity agent
WO2012026907A2 (en) Cefpodoxime proxetil formulations
EP2515862A1 (en) Rapidly dispersing pharmaceutical formulation with cefdinir
WO2004014337A2 (en) A process for the preparation of dispersible tablet of cephalexin
EP2566451B1 (en) Pharmaceutical compositions comprising cefditoren pivoxil
WO2007125541A1 (en) Pharmaceutical compositions of cefdinir
KR101019769B1 (en) Antibacterial Medicinal Composition of Enhanced Oral Absorptivity
EP1671635B1 (en) Noncrystalline antibacterial composition containing cefditoren pivoxil
JP3546208B2 (en) Antibacterial pharmaceutical composition with improved oral absorption
WO2011093821A1 (en) Effervescent formulations comprising cefdinir and clavulanic acid
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
US20070286901A1 (en) Novel Pharmaceutical Formulation of Cefixime for Enhanced Bioavailability
CN101461799B (en) Stable pravastatin medicament composition and preparation method thereof
JP2003300885A (en) Antibacterial pharmaceutical composition
WO1999032124A1 (en) Pharmaceutical compositios containing (s)-cefuroxime axetil and their use for the treatment of bacterial infections
JP2003012517A (en) Stable amorphous composition having improved dissolution
EP2663289A2 (en) Cefpodoxime proxetil formulations comprising taste regulating agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

EL Fr: translation of claims filed
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090508

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090919